Hepatitis C-Induced Hepatitis Flare in a Patient with Non-Hodgkin B-Cell Lymphoma Treated by Rituximab Including Chemotherapy (Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin - Vincristine, Prednisolone) Regimen
Hepatitis virus infections can lead to more critical outcomes such as severe hepatic dysfunction, failure, and fulminancy in the immunosuppressive patients other than immunocompetent individuals. It is globally accepted that reactivation of both hepatitis B virus and hepatitis C virus (HCV) occurs after chemotherapy and miscellaneous antibody treatments of malignant diseases or solid organ/bone marrow transplant in recipient patients. Especially among B-cell non-Hodgkin lymphoma (NHL) patients, according to various studies, the seroprevalance of HCV is higher than that of the general population. On the other hand, the role of HCV in the pathogenesis and etiology of NHL has been suggested. Today, cytotoxic drugs, corticosteroids, rituximab (RTX), and hepatotoxic regimens are administered to NHL patients. Specifically, it has been emphasized that the utilization of RTX (Anti CD20 antibody) regiments for B-cell NHL patients may result with flares in HCV patients conspicuously. Here, we report the case of an acute flare up due to HCV infection in a patient who underwent a 4 month course of RTX, containing chemotherapy against a B cell NHL (CD20+) disease and a
dramatic recovery from HCV infection at the end.